Related references
Note: Only part of the references are listed.Risk of Cancer Following the Use of N-Nitrosodimethylamine (NDMA) Contaminated Ranitidine Products: A Nationwide Cohort Study in South Korea
Hong Jin Yoon et al.
JOURNAL OF CLINICAL MEDICINE (2021)
The Association between Ranitidine Use and Gastrointestinal Cancers
Gerald McGwin
CANCERS (2021)
Methodological considerations when analysing and interpreting real-world data
Til Sturmer et al.
RHEUMATOLOGY (2020)
Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population
Jeffrey K. Lee et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice
Efrat Broide et al.
BMJ OPEN (2020)
Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies
Peipei Liu et al.
BRITISH JOURNAL OF CANCER (2020)
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Seng Chan You et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Comparison of First-Line Dual Combination Treatments in Hypertension: Real-World Evidence from Multinational Heterogeneous Cohorts
Seng Chan You et al.
KOREAN CIRCULATION JOURNAL (2020)
Proton pump inhibitor: The dual role in gastric cancer
Moon Kyung Joo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis
Kailin Jiang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility
Reidar Fossmark et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
Marc A. Suchard et al.
LANCET (2019)
Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis
Ryota Niikura et al.
GUT (2018)
Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study
Ka Shing Cheung et al.
GUT (2018)
Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) - Study section Digestive Diseases in Primary Care
Vincenzo Savarino et al.
DIGESTIVE AND LIVER DISEASE (2018)
Evaluating large-scale propensity score performance through real-world and synthetic data experiments
Yuxi Tian et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2018)
Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer
Il Ju Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2018)
Risk of gastric cancer development after eradication of Helicobacter pylori
Ka-Shing Cheung et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Association of Hemoglobin A(1C) Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin Analysis From the Observational Health Data Sciences and Informatics Initiative
Rohit Vashisht et al.
JAMA NETWORK OPEN (2018)
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
P. Malfertheiner et al.
GUT (2017)
Cohort Profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea
Juneyoung Lee et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2017)
Complications of Proton Pump Inhibitor Therapy
Michael F. Vaezi et al.
GASTROENTEROLOGY (2017)
Accuracy of an automated knowledge base for identifying drug adverse reactions
E. A. Voss et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2017)
Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden
Nele Brusselaers et al.
BMJ OPEN (2017)
Proton pump inhibitors affect the gut microbiome
Floris Imhann et al.
GUT (2016)
Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey
Woon Geon Shin et al.
HELICOBACTER (2016)
Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis
Yi-Chia Lee et al.
GASTROENTEROLOGY (2016)
Propensity score model overfitting led to inflated variance of estimated odds ratios
Tibor Schuster et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2016)
Active-comparator design and new-user design in observational studies
Kazuki Yoshida et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Negative Controls A Tool for Detecting Confounding and Bias in Observational Studies
Marc Lipsitch et al.
EPIDEMIOLOGY (2010)
Proton pump inhibitors and risk of gastric cancer: a population-based cohort study
A. H. Poulsen et al.
BRITISH JOURNAL OF CANCER (2009)
Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Non-Helicobacter pylori bacterial flora during acid-suppressive therapy:: differential findings in gastric juice and gastric mucosa
S Sanduleanu et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
